dc.contributor.author | Li, Le | |
dc.contributor.author | Muñoz Culla, Maider | |
dc.contributor.author | Carmona Igartua, Unai | |
dc.contributor.author | López, María Paz | |
dc.contributor.author | Yang, Fang | |
dc.contributor.author | Trigueros, Cesar | |
dc.contributor.author | Otaegui Bichot, David | |
dc.contributor.author | Zhang, Lianbing | |
dc.contributor.author | Knez, Mato | |
dc.date.accessioned | 2024-02-12T10:04:31Z | |
dc.date.available | 2024-02-12T10:04:31Z | |
dc.date.issued | 2016-05-05 | |
dc.identifier.citation | Biomaterials 98 : 143-151 (2016) | |
dc.identifier.issn | 1878-5905 | |
dc.identifier.issn | 0142-9612 | |
dc.identifier.uri | http://hdl.handle.net/10810/66061 | |
dc.description.abstract | We demonstrate a straightforward method to encapsulate siRNA into naturally available and unmodified
human apoferritin. The encapsulation into apoferritin is independent of the sequence of the siRNA and
provides superior protection for those sensitive molecules. High efficiency in transfection can be achieved
in human tumorigenic cells, human primary mesenchymal stem cells (hMSC) and peripheral blood
mononuclear cells (PBMCs). In contrast to Lipofectamine, highly effective gene silencing can be achieved
with ferritin as the delivery agent in both tumor cells and PBMCs at low siRNA concentrations (10 nM). As
an endogenous delivery agent, apoferritin does not induce immune activation of T- and B-cells in human
PBMCs. Apoferritin shows intrinsic anti-inflammatory effects and apoferritin-mediated delivery shows a
preference for immune-activated T- and B-cells, a natural selectivity which may turn useful for drug
delivery in case of infections or inflammatory diseases. | es_ES |
dc.description.sponsorship | M.K. and L.Z. greatly acknowledge financial support through
Marie Curie Actions (CIG) within project number 322158 (ARTEN).
The authors greatly acknowledge financial support by the Spanish
Ministry of Economy and Competitivity (MINECO) through project
number MAT2012-38161, the Diputaci on Foral de Guipúzcoa
through project number DFG15/006, and the Basque Government
through project number PI2013-56. | |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | |
dc.relation | info:eu-repo/grantAgreement/MINECO/MAT2012-38161 | |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.subject | siRNA | es_ES |
dc.subject | ferritin | es_ES |
dc.subject | primary cells | es_ES |
dc.subject | gene silencing | es_ES |
dc.subject | drug delivery | es_ES |
dc.title | Ferritin-mediated siRNA delivery and gene silencing in human tumor and primary cells | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | © 2016 Elsevier Ltd under CC BY-NC-ND license | * |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S0142961216301673 | |
dc.identifier.doi | 10.1016/j.biomaterials.2016.05.006 | |
dc.departamentoes | Procesos Psicológicos Básicos y su Desarrollo | |
dc.departamentoeu | Oinarrizko Psikologia Prozesuak eta Garapena | |